Literature DB >> 4108872

Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.

S Sirisinha, H N Eisen.   

Abstract

BALB/c mice were immunized with three A-myeloma proteins of BALB/c-2 or BALB/c origin (produced by plasmacytomas MOPC-315, MOPC-460, Adj. PC-22A). Noncross reacting antibodies were formed against Proteins-315 and 460, but the response to Protein-22A was marginal. Proteins-315 and 460 have anti-dinitrophenyl activity, and their reactions with the corresponding BALB/c antibodies were inhibited by dinitrophenyl ligands. It appears that antibodies can be formed in BALB/c mice against unique "idiotypic" determinants in the ligand-binding sites of some BALB/c mycloma proteins.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4108872      PMCID： PMC389606          DOI： 10.1073/pnas.68.12.3130

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  16 in total

1.  [A new allotype form of rabbit serum gamma-globulins, apparently associated with antibody function and specificity].

Authors:  J OUDIN; M MICHEL
Journal:  C R Hebd Seances Acad Sci       Date:  1963-07-17

Review 2.  The genetic control of immunoglobulin synthesis.

Authors:  J Oudin
Journal:  Proc R Soc Lond B Biol Sci       Date:  1966-11-22

3.  Affinity labeling of a mouse myeloma protein which binds nitrophenyl ligands. Kinetics of labeling and isolation of a labeled peptide.

Authors:  E J Goetzl; H Metzger
Journal:  Biochemistry       Date:  1970-03-03       Impact factor: 3.162

4.  Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315.

Authors:  H N Eisen; E S Simms; M Potter
Journal:  Biochemistry       Date:  1968-11       Impact factor: 3.162

Review 5.  Genetics of immunoglobulins in the mouse.

Authors:  M Potter; R Lieberman
Journal:  Adv Immunol       Date:  1967       Impact factor: 3.543

6.  Affinity and heterogeneity of antibodies induced by epsilon-2,4-dinitrophenylinsulin.

Authors:  J R Little; R B Counts
Journal:  Biochemistry       Date:  1969-07       Impact factor: 3.162

7.  Myeloma proteins with anti-hapten antibody activity: epsilon-2,4-dinitrophenyl lysine binding by the protein produced by mouse plasmacytoma MOPC-460.

Authors:  B M Jaffe; H N Eisen; E S Simms; M Potter
Journal:  J Immunol       Date:  1969-10       Impact factor: 5.422

8.  Variability in the lambda light chain sequences of mouse antibody.

Authors:  M G Weigert; I M Cesari; S J Yonkovich; M Cohn
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

9.  Experimental approaches tohomogenous antibody populations. iIndividual antigenic specificity, cross specificity and diversity of human antibodies.

Authors:  H G Kunkel
Journal:  Fed Proc       Date:  1970 Jan-Feb

10.  Quantitative investigations of idiotypic antibodies. IV. Inhibition by specific haptens of the reaction of anti-hapten antibody with its anti-idiotypic antibody.

Authors:  B W Brient; A Nisonoff
Journal:  J Exp Med       Date:  1970-11       Impact factor: 14.307
View more
  38 in total

1.  Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.

Authors:  Solveig Klaebo Reitan; Kristian Hannestad
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

2.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

Review 3.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 4.  Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.

Authors:  Flavio E Baio; Larry W Kwak; Jinsheng Weng
Journal:  Am J Blood Res       Date:  2014-12-15

Review 5.  Anti-idiotypic antibodies as probes of cell surface receptors.

Authors:  G N Gaulton; M S Co; H D Royer; M I Greene
Journal:  Mol Cell Biochem       Date:  1984-11       Impact factor: 3.396

6.  An experimental immunocytoma model in /LOU/M/Ws1 X CFY/F1 rats: neoplastic cells as targets of the host's immune apparatus.

Authors:  E Puskás; F Uher; J Gergely; H Bazin
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

Review 7.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

8.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Specific suppression of the antibody response by antibodies to receptors.

Authors:  H Cosenza; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

10.  Myeloma proteins as tumor-specific transplantation antigens.

Authors:  R G Lynch; R J Graff; S Sirisinha; E S Simms; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.